Iowa House Bill HF2009

Iowa 2025-2026 Regular Session

• Introduced: 1/13/26
• Refer: 1/13/26

Caption

A bill for an act relating to manufacturers and distributors of 340B drugs.

Impact

HF2009 is expected to have a significant impact on healthcare accessibility, particularly for entities that utilize 340B pricing to serve underserved populations. By restricting the ability of manufacturers and distributors to interfere with the distribution of these drugs, the bill aims to ensure that covered entities can effectively obtain necessary medications without obstruction. This change could improve access to essential drugs for many patients, particularly those relying on safety-net providers.

Summary

House File 2009 (HF2009) is legislation aimed at regulating the interaction between manufacturers and distributors of 340B drugs, which are outpatient drugs sold at reduced prices to certain healthcare entities. The bill establishes definitions for key terms such as '340B drug', 'manufacturer', and 'distributor', outlining the roles and responsibilities of each party involved. A significant provision of the bill prohibits manufacturers and distributors from denying or interfering with the acquisition of these drugs by covered entities or their contract pharmacies unless restricted by federal regulations.

Contention

The bill may draw criticism from various stakeholders, particularly in the pharmaceutical industry, who may argue that restrictions on distribution could affect pricing structures or supply chains. Supporters of HF2009 advocate that it promotes fair access to medications, whereas opponents might contend it could undermine the financial viability of manufacturers or lead to increased costs in other areas as they adapt to new regulatory frameworks. The balance of interests between pharmaceutical companies and healthcare providers is likely to be a point of contention during debates over the bill.